Core Viewpoint - The company, Maipu Medical (301033), will resume trading of its shares on June 6, 2025, following the approval of a significant asset acquisition and fundraising plan by its board of directors [1] Group 1: Company Actions - The company held its 10th meeting of the 3rd board of directors on June 5, where it approved the proposal for issuing shares and cash to acquire assets, along with related fundraising and connected transactions [1] - The audit and evaluation of the assets involved in this transaction are not yet completed, and the company will convene another board meeting to review the matters once the relevant work is finished [1] Group 2: Regulatory Requirements - The transaction is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission before it can be officially implemented, indicating a level of uncertainty [1] - The company will continue to advance this transaction and strictly fulfill its information disclosure obligations [1]
迈普医学：公司股票将于6月6日复牌 继续推进发行股份及支付现金购买资产并募集配套资金暨关联交易事项